Reboxetine: a review of antidepressant tolerability.

摘要: The tolerability of reboxetine was evaluated in 2613 adult (aged 18-65 years) or elderly > 65 patients with depressive illness treated reboxetine, comparator agents placebo, who entered both short- and long-term, controlled uncontrolled clinical trials. adverse-event profile acute depression established by comparison placebo 746 patients. Overall, 69% 373 experienced adverse events compared 57% the group. majority were moderate severity, discontinuation because low comparable (8%) (7.5%) When imipramine, better tolerated. Most side-effects less common than imipramine cohort, fewer receiving (10% patients; 11% patients) discontinued treatment those (14% 16% patients). Compared fluoxetine, total frequency similar reboxetine-treated (67%) fluoxetine-treated (65%). In fluoxetine group, 7% to 12% group corresponding a 12-month placebo-controlled study, groups (reboxetine 4%; 1%), only marginally higher (28%) (23%). no consistent changes found laboratory tests electrocardiogram recordings there indication withdrawal symptoms upon abrupt discontinuation. Reboxetine, novel selective noradrenaline reuptake inhibitor, is well tolerated adults during long-term for depression.